Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | 10% owner | November 24, 2025 | December 18, 2025 |
| Mitesco, Inc.tnty · Entity 8540 | Director | February 07, 2017 | March 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date November 24, 2025 · Filed December 18, 2025
Jointly reported with 10X Fund, L.P., 10X Capital Management, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,614,457 |
Last balance in matching sequence
After 2025-12-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-11-24 · Other · Disposed 24,000 · Balance 5,645,138 F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Row 2 · 2025-12-16 · Sale · Disposed 30,681 · Balance 5,614,457 F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Mitesco, Inc.
Report date February 07, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 100,000 |
| Restricted Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 200,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 15:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 30,681 | $6.66 | $204,335.46 |
DisclosureSEC source: 0001493152-25-028303 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,614,457 F3 · price: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:57 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 120,000 | $5.73 | $687,600.00 |
DisclosureSEC source: 0001493152-25-026204 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,682,207 F3 · price: The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2025 Filed Dec 8, 2025 18:21 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 132,069 | $5.73 | $756,755.37 |
DisclosureSEC source: 0001493152-25-026587 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,670,138 F3 · price: The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:57 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 30,000 | $5.47 | $164,100.00 |
DisclosureSEC source: 0001493152-25-026204 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,802,207 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 18:21 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 30,000 | $5.47 | $164,100.00 |
DisclosureSEC source: 0001493152-25-026587 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,802,207 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 24, 2025 Filed Dec 18, 2025 15:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 24,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-028303 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,645,138 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 40,000 | $5.25 | $210,000.00 |
DisclosureSEC source: 0001493152-25-021959 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,832,207 F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2025 Filed Oct 25, 2025 00:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 30,000 | $4.94 | $148,200.00 |
DisclosureSEC source: 0001493152-25-019379 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,872,207 F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2025 Filed Oct 25, 2025 00:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 20,000 | $4.93 | $98,600.00 |
DisclosureSEC source: 0001493152-25-019379 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902,207 F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 19 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 18 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 17 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 70,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 16 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 40,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 15 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 30,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 14 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 25,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 13 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 46,875 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 12 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,875 Underlying: Common Stock · 31,250 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were exercisable at time of exercise. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 40,000 | $1.11 | $44,400.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 11 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,045,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 40,000 | $1.98 | $79,200.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 10 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,005,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 70,000 | $2.11 | $147,700.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 9 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 40,000 | $2.11 | $84,400.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 8 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 895,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 30,000 | $2.86 | $85,800.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 7 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 25,000 | $4.72 | $118,000.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 6 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 825,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 46,875 | $2.39 | $112,031.25 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 5 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 31,250 | $0.89 | $27,812.50 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 4 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 753,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 3 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,416 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| February 04, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,416 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| February 03, 2025 Filed Jun 11, 2025 22:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,416 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| December 19, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 8 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,416 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| September 30, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 6 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747,016 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| July 03, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 7 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,416 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| June 26, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 5 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,016 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| May 17, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 4 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,416 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| May 17, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 3 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754,816 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| May 10, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 759,216 F3 · price: No consideration was received for the shares, which were transferred by gift to relatives. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 15:36 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 3,677 | $3.06 | $11,251.62 |
DisclosureSEC source: 0001493152-24-015877 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 5,922,207 F1 · ownership.direct: The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 22, 2024 Filed Apr 25, 2024 15:36 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 21,323 | $3.06 | $65,248.38 |
DisclosureSEC source: 0001493152-24-015877 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 5,925,884 F1 · ownership.direct: The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2024 Filed Jun 11, 2025 21:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,616 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| September 30, 2023 Filed Apr 25, 2024 15:37 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001493152-24-015879 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,616 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| March 31, 2023 Filed Apr 25, 2024 15:37 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001493152-24-015879 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 761,616 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000010 · form4.xml · derivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-26 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2023. Read SEC document |
| December 21, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 61,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 6 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,947,207 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 21, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 5 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,008,614 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 21, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 16,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 4 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011,691 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 21, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 17,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 3 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,027,741 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2022 Filed Dec 1, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001493152-23-043431 · ownership.xml · nonDerivative · entry 5 CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,616 F2 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F3 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F2 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
| July 29, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 90,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,044,858 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 29, 2022 Filed Jan 31, 2023 19:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 33,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-003128 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,135,444 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2022 Filed Aug 9, 2022 19:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.09 | $20,870.00 |
DisclosureSEC source: 0001493152-22-021740 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,168,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2022 Filed Dec 1, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001493152-23-043431 · ownership.xml · nonDerivative · entry 4 CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,616 F2 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F3 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. F2 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.